Treatment with a Platelet Activating Factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock,Clinical & Experimental Allergy

当前位置： X-MOL 学术 › Clin. Exp. Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment with a Platelet Activating Factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2019-12-10 , DOI: 10.1111/cea.13540
Charles Tacquard _{1,

2} , Walid Oulehri _{1,

3} , Olivier Collange _{1,

3} , Lene H Garvey _{4,

5} , Susan Nicoll ₆ , Nicolas Tuzin ₂ , Bernard Geny ₃ , Paul M Mertes _{1,

3}

Affiliation

In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet‐activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.

中文翻译：

在致死性过敏性休克啮齿动物模型中，使用血小板激活因子受体拮抗剂治疗可改善血流动力学并降低肾上腺素需求

在某些情况下，尽管快速使用肾上腺素，过敏性休克 (AS) 仍然是致命的。高剂量的肾上腺素与严重的并发症有关。血小板激活因子 (PAF) 在 AS 期间大量分泌，高血浆水平与 AS 严重程度增加相关。

更新日期：2019-12-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文